Sarepta Therapeutics, Inc. (SRPT)
16.23
+0.14
(+0.87%)
USD |
NASDAQ |
Mar 05, 16:00
16.05
-0.18
(-1.11%)
Pre-Market: 08:41
Sarepta Therapeutics Cash from Investing (TTM) : 69.64M for Dec. 31, 2025
Cash from Investing (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (TTM) Benchmarks
| Merck & Co., Inc. | -13.74B |
| Pfizer Inc. | -1.351B |
| REGENXBIO, Inc. | -- |
| Keros Therapeutics, Inc. | -1.551M |
| Alnylam Pharmaceuticals, Inc. | 436.33M |